Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has become an integral component of weight management and type 2 diabetes treatment due to its potent efficacy in glycemic control and cardiovascular risk reduction
Contact your GP, prescribing clinician, or call 999/111 if you experience: Severe or persistent vomiting or abdominal pain Signs of pancreatitis : severe upper abdominal pain, which may radiate to the back, with or without vomiting this requires urgent medical assessment Symptoms of a serious allergic reaction : rash, swelling of the face, lips, tongue or throat, or difficulty breathing These are rare but important safety signals, as outlined in the Wegovy Summary of Product Characteristics (SmPC) approved by the MHRA
They are practical observations
One such side effect is possible eye issues and vision loss, for which there is currently a great deal of conflicting information
How It Works Activates both GLP-1 and GIP receptors for a broader metabolic impact Reduces appetite and increases satiety through two hormonal pathways Enhances insulin sensitivity more aggressively than GLP-1 alone Supports reduction of visceral fat the deep abdominal fat most strongly associated with metabolic disease Improves blood sugar regulation through a dual insulin-stimulating mechanism Clinical Results In the SURMOUNT-1 trial, Tirzepatide produced average weight loss of up to 20% of body weight outperforming Semaglutide in head-to-head comparisons
Another factor could be nutrient deficiencies
